Therefore, we sought to perform a systematic review and meta-analysis examining the efficacy of SGLT2 inhibitors in patients with HF, with or without diabetes, specifically interested in mortality and hospitalization endpoints, as well as the outcomes in subpopulations of HF patients. Here, SLC5A2 is linked to diabetes mellitus.